Goldman Sachs Upgrades Novo Nordisk A/S (NVO) to Buy
More News related to NVO
- Novo Nordisk is Changing Possibilities in Hemophilia
- New Study Finds Significant Inconsistency With How Diabetes Quality of Care is Measured
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
- Trading Outlook for Generex Biotechnologies Corp. Issued by InvestorSoup.com
- Novo Nordisk Wins Design Award for NovoTwist(TM) Needle
Goldman Sachs upgrades Novo Nordisk A/S (NYSE: NVO) from Neutral to Buy, saying Levemir to benefit from Lantus safety fears after four studies were published showing the potential of increased cancer risk with Lantus. The firm said the negative press for Lantus will help sales of Novo's Levemir.
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products.
Related Categories
UpgradesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
